Lipum

Executive Summary

Lipum AB is a Swedish clinical-stage biopharmaceutical company developing novel treatments for chronic inflammatory diseases by targeting Bile Salt-Stimulated Lipase (BSSL), a previously undrugged immune target. Its lead candidate, SOL-116, is a humanized monoclonal antibody with a unique mechanism of action aimed at modulating the immune response in conditions such as rheumatoid arthritis, inflammatory bowel disease, and other autoimmune disorders. Founded in 2010 and based in Umeå, Lipum has advanced SOL-116 through preclinical development and into Phase 1 clinical trials, demonstrating an acceptable safety profile and early signs of biological activity. The company remains private and has not disclosed funding details or valuation, but its innovative approach to inflammation could address significant unmet medical needs. As a Phase 1-stage firm, Lipum's near-term value hinges on successful clinical data readouts and its ability to secure partnerships or additional financing to advance through later-stage development.

Upcoming Catalysts (preview)

• Q2 2026Phase 1 safety and biomarker data readout65% success
• Q4 2026Initiation of Phase 2a proof-of-concept trial40% success
• TBDLicensing or collaboration agreement with larger pharma20% success